Investigating Potential claims – PolarityTE
The White Law Group is investigating potential claims involving broker dealers who may have unsuitably recommended PolarityTE to investors. If you are concerned about your investment in PolarityTE, the securities attorneys at The White Law Group may be able to help you.
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company “focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences,” according to its website.
The company’s stock has fallen approximately 60% since June 2018 to $14.16/per share at close on Friday, October 12, 2018.
Broker dealers are required to perform adequate due diligence on all investment recommendations. They must ensure that each investment is suitable for the investor in light of the investor’s age, risk tolerance, net worth, financial needs, and investment experience.
If a broker makes an unsuitable investment recommendations or fails to adequately disclose the risks associated with an investment they may be liable for investment losses.
FINRA operates the largest securities dispute resolution forum in the United States, and has extensive experience in providing a fair, efficient and effective venue to handle a securities-related dispute.
If you are concerned about your investment in PolarityTE or another investment, The White Law Group may be able to help you. For a free consultation with a securities attorney, please contact The White Law Group at 1-888-637-5510.
The White Law Group is a national securities fraud, securities arbitration, and investor protection law firm with offices in Chicago, Illinois and Vero Beach, Florida. For more information on the firm, visit www.WhiteSecuritiesLaw.com.